• Company
• Reimb progress of 2 NMOSD drugs receive attention in 2H
• by Eo, Yun-Ho Jun 28, 2023 05:52am

• Policy
• 4 Vemlidy latecomers reimbursed in Korea
• by Lee, Tak-Sun Jun 27, 2023 05:48am

• Company
• B-cell lymphoma drug Polivy applies for reimb again
• by Eo, Yun-Ho Jun 27, 2023 05:47am

• Policy
• Pediatric orphan drug Qarziba·Bylvay selected as the No. 1
• by Lee, Jeong-Hwan Jun 27, 2023 05:47am

• Company
• Boryung Lenvima passed the first hurdle of the patent challe
• by Kim, Jin-Gu Jun 26, 2023 05:53am

• Policy
• Cibinqo is slightly cheaper than Rinvoq in Korea
• by Lee, Tak-Sun Jun 26, 2023 05:53am

• Company
• Entresto’s reimb for HFrEF is extended again
• by Eo, Yun-Ho Jun 26, 2023 05:53am

• Opinion
• [Reporter's view] Where's the wrong answer note
• by Kim, Jin-Gu Jun 26, 2023 05:53am

• Policy
• Opsumit price cut by 30%
• by Kim, Jung-Ju Jun 26, 2023 05:52am

• Policy
• Breast cancer Tx Ibrance’s AE rate at 86%...6yr PMS results
• by Lee, Hye-Kyung Jun 23, 2023 05:45am